source
- Multispecific antibodies push CDMOs to redesign development platformsManufacturers are moving beyond traditional monoclonal-antibody platforms as multispecific therapeutics gain traction. The new design model relies on molecular engineering, advanced analytics, and…
- CAR T therapy moves from cancer to autoimmune disease, leveraging oncology safety lessonsCell therapy that transformed treatment of blood cancers is now being tested for autoimmune disorders, according to a recent opinion piece. Early cancer trials showed high complete response rates…